Prostate cancer is the number one cancer in males in Africa, both in terms of incidence and mortality, accounting for 40,000 (13%) male cancers and 28,000 (11.3%) male cancer-associated deaths. In the developed world, the probability of being diagnosed with cancer is more than twice as high as in developing countries. In developing countries, most cancer victims are diagnosed at late stage, with incurable tumors, pointing to the need for education schemes and better detection programs. This study assessed knowledge, attitudes and perceptions of prostate cancer among male staff of the University of Nigeria. This cross-sectional descriptive study was carried out with 655 male staff who agreed to participate and were recruited on giving oral consent. A self-administered questionnaire, written in English was used. The mean percentage knowledge score was 71.2%. Some 57.8% of respondents had a high knowledge level of prostate cancer. The mean percentage attitude score was 69.9%. More than half (60.8%, n = 397) of respondents had a positive attitude towards prostate cancer screening and treatment. The mean percentage perception score was 60.0%. More than half (53.9%, n = 351) of respondents had a negative perception of prostate cancer screening and treatments. The staff of the University of Nigeria have appreciable knowledge and a positive attitude with regard to prostate cancer. A significant proportion of staff however, exhibited poor knowledge and negative attitudes and perceptions of prostate cancer screening and treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648405 | PMC |
http://dx.doi.org/10.22034/APJCP.2017.18.7.1961 | DOI Listing |
Endocr Relat Cancer
January 2025
S Dehm, Masonic Cancer Center, University of Minnesota, Minneapolis, United States.
Treatment for castration-resistant prostate cancer (CRPC) primarily involves the suppression of androgen receptor (AR) activity using androgen receptor signaling inhibitors (ARSIs). While ARSIs have extended patient survival, resistance inevitably develops. Mechanisms of resistance include genomic aberrations at the AR locus that reactivate AR signaling, or lineage plasticity that drives emergence of AR-independent phenotypes.
View Article and Find Full Text PDFJAMA Netw Open
January 2025
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.
Importance: The phase 3 randomized EMBARK trial evaluated enzalutamide with or without leuprolide in high-risk nonmetastatic hormone-sensitive prostate cancer. Eligibility relied on conventional imaging, which underdetects metastatic disease compared with prostate-specific membrane antigen-positron emission tomography (PSMA-PET).
Objective: To describe the staging information obtained by PSMA-PET/computed tomography (PSMA-PET/CT) in a patient cohort eligible for the EMBARK trial.
Int Urol Nephrol
January 2025
Faculty of Medical Sciences, Pharmacology and Toxicology Department, University of Kragujevac, Kragujevac, Serbia.
Purposes: Intermediate-risk prostate cancer (IR PCa) is the most common risk group for localized prostate cancer. This study aimed to develop a machine learning (ML) model that utilizes biopsy predictors to estimate the probability of IR PCa and assess its performance compared to the traditional clinical model.
Methods: Between January 2017 and December 2022, patients with prostate-specific antigen (PSA) values of ≤ 20 ng/mL underwent transrectal ultrasonography-guided prostate biopsies.
Sleep Breath
January 2025
Clinical Internal Medicine Department, Shanghai Health and Medical Center, Wuxi, 214065, People's Republic of China.
Background: Obstructive sleep apnea has been associated with various urinary system diseases, including prostatic hyperplasia and nocturia. Recently, it has been linked to prostate cancer. This study investigated the relationship between the apnea hypopnea index, prostate-specific antigen (PSA) levels, and changes in PSA.
View Article and Find Full Text PDFAnn Surg Oncol
January 2025
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Background: AT-rich interaction domain 4B (ARID4B) is a transcriptional activator that regulates the phosphatidylinositol 3-kinase (PI3K)/AKT pathway in prostate cancer. However, the role of ARID4B in hepatocellular carcinoma (HCC) has remained unclear.
Methods: This study included 162 patients who had undergone primary hepatic resection for HCC between 2008 and 2019.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!